How AI Biotech Founders Should Position for Investors in 2026

In January 2026, a widely shared post captured the divide cleanly: investors at San Francisco AI labs are near-total believers that AI will revolutionize drug discovery, while healthcare investors in New York are near-total skeptics who think it is worth roughly zero (buildmvpfast). Both groups are looking at the same evidence. That is the environment you are raising into.

Table of contents

The capital is real. PitchBook reported that venture investors put about $2.7 billion into AI drug-development companies through the first three quarters of 2025, even as overall biotech funding slowed — a gap that, in their words, reflects investor conviction that AI can drive real R&D efficiency. Precedence Research projects the drug industry’s AI investment will reach $2.51 billion in 2026 on its way to $16.49 billion by 2034. And the megarounds keep landing: Isomorphic Labs’ $2.1 billion Series B in May 2026 was one of the largest private rounds ever in AI drug discovery.

But the skepticism is just as real, and it has hardened. As of early 2026, no AI-discovered drug had yet cleared clinical trials — a fact every serious investor now knows. Drug Target Review framed the year as an inflection point between clinical validation and market volatility: 2026 will either substantiate the decade-long AI thesis or force a hard recalibration.

For a founder raising seed, Series A, or Series B capital this year, that split defines the entire positioning challenge. The technology alone will not carry your raise — too many companies now have it. Your job is to position around what an increasingly discerning investor can no longer assume: a defensible data advantage, validated execution, capital discipline, and a story calibrated precisely to your stage. This is how to do that.

The 2026 landscape: capital is flowing, but conviction is split

Understanding the room is the prerequisite for positioning into it.

The money is real — and concentrated

AI is now the rare bright spot in an otherwise cautious biotech market. Early-stage activity is genuine: over the trailing twelve months, seed and Series A rounds made up about 65% of AI drug-discovery deals. But the dollars tell a more mature story — a small number of later-stage rounds captured a disproportionate share of capital, and the largest outcomes went overwhelmingly to companies that already had prior validation or repeat financing. Translation: investors will fund many early hypotheses cheaply, but they reserve the serious money for proof.

So is the skepticism

The doubt is not coming from outsiders. Brendan Frey, a founder in the space, put it bluntly: AI’s drug-discovery track record over the past decade has been a run of failures (buildmvpfast). The structural reasons are sobering — roughly 85% of drug candidates fail in clinical trials, and it still takes 10 to 15 years to go from lab to approval. AI improves efficiency inside that process; it does not repeal the biology. Analysts now place only about a 60% probability on the first AI-discovered drug winning approval even by 2027 or 2028.

What the split means for you

A divided room is actually an opportunity. It means your positioning has to do two jobs at once: signal enough ambition to excite the believers, and enough rigor and honesty to disarm the skeptics. Founders who pitch pure AI optimism read as naive to half the table. Founders who can name the limitations and show why their specific approach overcomes them read as credible to the whole table. Credibility, not hype, is the scarce asset in 2026.

Stop selling the algorithm — it is no longer your differentiator

The most common positioning mistake in 2026 is leading with the model. That worked in 2021. It does not work now.

AI models are commoditizing; proprietary data is the moat

The frontier has shifted. Open-source models, foundation models, and accessible compute mean the algorithm itself is increasingly a commodity — even a company like Absci has open-sourced de novo antibody designs from its generative platform. What competitors cannot copy is your unique, high-quality biological data generated at scale. As Bessemer’s investment team argues, the durable advantage now sits in biology-native data infrastructure, not model weights. DrugPatentWatch is blunter still: the data moat is more durable than the underlying algorithms, which are increasingly commoditized.

What “defensible” actually means to a 2026 investor

Ilya Trotsyuk, evaluating AI biotech deals, describes an investable company as one that has built or secured datasets competitors cannot easily replicate, paired with traction among the right users — researchers or pharma teams actually using the tool in their work, not just a thesis on a slide. The flip side is a stated red flag: a fully open-source, non-proprietary stack with little defensible IP. If your pitch cannot answer “what here can’t be rebuilt by a well-funded competitor in twelve months?”, you do not yet have a position — you have an idea.

Reframe the pitch

Position your model as the engine that compounds a proprietary data asset, not as the product. The narrative that lands: “We generate biological data competitors can’t access, our models learn from it, that improves what we generate next, and the loop widens our lead with every cycle.” That is a moat story. “Our model beats AlphaFold 3 on benchmark X” is, by itself, a press release.

Position around proof, not promise

In a skeptical year, every claim you make is discounted unless you can show the receipt. Build your positioning on three kinds of proof.

A validated wet-lab feedback loop

Investor diligence in 2026 explicitly includes assessing wet-lab execution — because in-silico predictions still have to survive contact with real biology. The companies that impress can point to a closed loop: predictions tested against physical experiments fast enough to retrain the models continuously. Absci, for instance, can take an AI-designed candidate to wet-lab validation in as few as six weeks, with automated labs generating proprietary data at scale. If you have a loop like this, it belongs near the front of your story.

Capital efficiency: the cost-per-IND story

One metric is quietly becoming the institutional yardstick for AI-native companies: cost-per-IND. Analysts now treat firms that can generate an IND filing for under $50 million as holding a structural advantage over traditional peers spending upward of $200 million. If your approach compresses that number, make it the spine of your financial narrative. Capital efficiency is exactly what a cautious 2026 investor wants to hear, because it lowers the risk on every dollar they commit.

Validation from people who can judge you

External validation substitutes for the clinical proof the whole field still lacks. Pharma partnerships are the strongest signal available — Recursion’s collaborations with Bayer, Roche, and Sanofi carry the potential for more than $20 billion in milestones before royalties, and Isomorphic’s deals with Lilly and Novartis are worth nearly $3 billion in potential value. You may not have nine-figure pharma deals at seed, but any credible external validation counts: a paying pharma pilot, a competitive benchmark win, a notable scientific co-founder, or revenue. The most advanced player in the field, Insilico Medicine, anchors its credibility on being the only company that can point to a Phase 2a human readout for a fully AI-discovered asset, published in Nature Medicine, alongside real revenue. Whatever your version of proof is, lead with it.

Are you AI-native or AI-enhanced? Position accordingly

This is the distinction most founders blur — and blurring it is costly, because investors value the two models on entirely different terms.

AI-native (platform) positioning

If AI is the core of your company — the data engine that produces many programs — you are a platform company. Investors will value you on pipeline optionality and data moat: how many active programs, how defensible the proprietary dataset, and what it would cost a competitor to replicate the platform. Your positioning should emphasize repeatability and compounding returns — that the platform gets better and cheaper per asset over time. The risk to manage: platform stories can sound like vaporware without at least one concrete asset advancing to ground them.

AI-enhanced (asset-first) positioning

If you are fundamentally a therapeutics company using AI to move faster and smarter, you are an asset company. You will be valued on the risk-adjusted net present value (rNPV) of your lead candidates, with your AI history informing — but not replacing — standard probability-of-success assumptions. Position AI as a credible accelerant of a specific, high-value program, not as the headline. Here, the danger is over-claiming the AI and underselling the asset; serious therapeutics investors will see through it.

Pick a lane

You can be a platform with a lead asset or an asset company with a strong computational edge — but you must decide which story is primary and which is supporting. Investors punish the blur because it signals you do not know what you are. Choose the framing that matches both your reality and the investors you are targeting, and make everything in your materials reinforce it.

Calibrate the story to your stage

What proves you out at seed will underwhelm at Series B. Match the burden of proof to the round.

Seed: team, thesis, and the proprietary wedge

At seed, you are selling a credible team and a sharp data thesis. Investors fund many hypotheses at this stage, so the bar is conviction, not clinical data. Position around: why your team is uniquely able to generate or access data others can’t, the specific wedge that becomes a moat, and a clear “why now.” A defensible data-acquisition plan matters more than a finished platform.

Series A: the validated loop and early proof

By Series A, the market expects evidence the engine works. Investors increasingly favor companies with validated datasets, working wet-lab feedback loops, and a clear regulatory strategy — and ideally an early partnership or pilot. Your positioning should show the loop turning: data in, validated predictions out, models improving. A favorable cost-per-IND trajectory is a powerful A-stage argument.

Series B: assets in or near the clinic

At Series B, the conversation is about real programs. Investors increasingly favor companies with at least one asset in IND-enabling studies or early clinical work. Platform companies must show the model is repeatable across multiple programs, not a one-off; asset companies must show their lead candidate’s progression and a credible regulatory path. Either way, “promising platform” is no longer enough — the question is what you have actually put into development.

Address the risks investors are already pricing in

Skeptical investors have a checklist of concerns. Pre-empting them is itself a positioning move — it signals you see the field as clearly as they do.

The translational reality. Do not claim AI eliminates clinical risk. It improves efficiency within existing models; it does not close the gap between animal models and human biology. Acknowledging this earns you credibility you can spend elsewhere.

Data quality and IP. About 68% of executives cite poor data quality and governance as the main reason AI initiatives fail, and pharmaceutical data is notoriously fragmented. Open questions about who owns AI-suggested targets and AI-designed molecules remain unresolved and can spook investors. Have crisp answers on data provenance, governance, and IP.

Supply-chain exposure. Many AI-first biotechs are “virtual” — they design in the cloud and outsource synthesis and testing to contract labs, a large share of it to Chinese CROs. With WuXi alone estimated to touch up to 25% of drugs used in the US, geopolitical and supply-chain risk is now a live diligence topic. Show you have thought about resilience.

Regulatory path. The FDA proposed a framework in January 2025 for validating AI models used in drug submissions. Demonstrating fluency with the emerging regulatory expectations — model explainability, data audits — signals maturity and reduces perceived risk.

Make your positioning visible before you raise

Here is what founders consistently underrate: your positioning is being evaluated long before your pitch meeting. Investors research you first — your company, your thinking, your public point of view. In a year when 2026 is being called the “year of deployment” and the field is crowded with similar-sounding claims, the founders who are already a recognized, credible voice on their specific approach walk into the room with the skepticism partly pre-empted.

This is why a raise functions like a marketing campaign, not a single event. Your positioning has to be consistent everywhere an investor encounters you — the deck, your LinkedIn presence, your published thinking, and the data room — so that each touchpoint reinforces the same clear story rather than introducing a new one. Fragmented messaging reads as a fragmented company. The work of building that visible, coherent narrative ideally starts 12 to 24 months before you open a round, not the week you start pitching.

A practical 12-month roadmap for positioning your AI biotech

If the work starts a year or more before the raise, here is what that year looks like in practice — the positioning infrastructure that turns a cold first meeting into a warm one.

Q1 — Narrative development and lane clarity (Months 1–3)

The first quarter builds the strategic foundation every later investor interaction depends on.

  • Pick your lane. Decide honestly whether you are an AI-native platform or an AI-enhanced asset company — and which story is primary. Each has a different investor audience, narrative, and proof standard. Build every material around the choice.
  • Define the specific role of your AI. Write a two-paragraph technical description of what your AI does, what it was trained on, what predictions it makes, and how those predictions are validated. This becomes your answer to the inevitable “tell me specifically how your AI works” question.
  • Audit your existing materials. Review deck, one-pager, and website against the AI-washing test: is every AI claim specific, is every computational output tied to biological confirmation, and is the data moat — not the model — the headline?
  • Build your competitor answer. “How are you different from Recursion / Isomorphic / Insilico?” is coming in every meeting. Ground the answer in your proprietary data advantage, not in dismissing theirs.
  • Define your target investor list. Not all life sciences VCs have an AI biotech thesis. Firms active in the space include ARCH Venture Partners, OrbiMed, Sofinnova, and Flagship Pioneering — research which funds actually wrote AI biotech checks in the past eighteen months and build your list from verified thesis fit.

Q2 — Evidence building and early relationships (Months 4–6)

The second quarter generates the proof points and early touchpoints that anchor the raise narrative.

  • Close one prediction-to-biology data loop. If you have not yet done it, make it your highest-priority scientific goal. A computational prediction confirmed by a wet-lab assay or animal model is the most powerful single positioning asset at this stage.
  • Open your first pharma conversation. Even an informal scientific exchange with a pharma research team is worth starting. Formal deals take time; the relationship-building that precedes them should begin now, through conference networks, mutual advisors, and LinkedIn.
  • Publish your first technical thought-leadership piece. A substantive article at the intersection of your AI approach and your disease area starts the public record of expertise investors will research before meeting you. Use specific data, named sources, and a FAQ section for GEO discoverability.
  • Begin value-first investor outreach. Reach out to 10–15 target investors with messages referencing your specific approach and their fund’s stated thesis. “I’d value your perspective on how you think about AI validation at preclinical stage” outperforms “I’d like to share our deck.”
  • Register for one major AI-plus-bio event. Events like BIO International, Biotech Showcase, and emerging AI-in-life-sciences venues put investors, partners, and press in one place. Apply for a speaking slot early.

Q3 — Visibility and platform validation (Months 7–9)

The third quarter converts your evidence base and early relationships into visible, compounding credibility.

  • Speak at your target conference. A panel or short talk generates investor visibility, creates a speaker bio that surfaces in Google and AI search, and positions you as a participant in the field’s scientific conversation rather than a founder simply seeking capital.
  • Formalize or announce a partnership. Even a modest research agreement, collaborative publication, or named scientific advisory relationship is a significant signal. Time it with your conference attendance and LinkedIn activity for maximum reach.
  • Pursue trade-press coverage. Introduce yourself to journalists at STAT News, Endpoints News, and Fierce Biotech as an expert source on AI drug discovery. A single earned-media quote — about the field, not your raise — is a persistent, AI-citable credibility asset.
  • Begin quarterly investor updates. A brief, substantive update to opted-in investors and advisors — the quarter’s key validated proof point, a pipeline milestone, a partnership development, and what you’re looking for next — frames steady scientific progress, not a solicitation.

Q4 — Raise preparation and pipeline activation (Months 10–12)

The fourth quarter converts nine months of positioning into a formal process.

  • Update all materials with current proof. Every piece of biological confirmation, every partnership, every regulatory milestone from the prior nine months belongs in the refreshed deck and one-pager. A biotech pitch deck should highlight your value proposition, market size, scientific data, team credentials, and exit strategy. Materials reflecting last year’s position misrepresent your company today.
  • Run simultaneous, not sequential, outreach. Reaching your full target list inside a two-week window signals momentum and creates the competitive dynamics that improve terms. Sequential outreach stalls as investors wait to see who else is in.
  • Prepare the five hardest answers. Every AI biotech investor will ask: (1) what AI-generated prediction has been confirmed biologically; (2) why a better-funded competitor can’t replicate your data moat; (3) what your FDA strategy for AI-assisted development is; (4) what your external validation says about the platform; (5) where the evidence is that your AI actually compresses the timeline. Have honest, specific, data-backed answers ready before the first meeting.
  • Build the AI-specific data room. AI biotech diligence adds elements traditional diligence does not: model architecture documentation, training-data provenance and governance, validation methodology, and IP strategy around AI-generated discoveries. Organize these proactively — being asked and not having them is real process friction.

The bottom line

In 2026, AI is no longer the differentiator in AI biotech — every founder in the room has it. What separates the founders who raise from the ones who stall is positioning: a defensible data moat rather than a model demo, validated execution and capital efficiency rather than promise, a clear choice between platform and asset framing, and a story matched precisely to the stage you are raising at. Layer on an honest reckoning with the risks investors already see, made visible consistently before you ever pitch, and you address both halves of a divided market — the believers and the skeptics — at once.

The technology got you into the conversation. Positioning is what wins the term sheet.

Book a Strategy Call to pressure-test your investor positioning before your next raise, or Explore My Services to see how founder positioning, visibility, and investor outreach work together.

Frequently Asked Questions

Lead with a defensible data advantage, not the model. In 2026 the algorithm is increasingly commoditized, so the durable moat is proprietary biological data generated at scale and a validated wet-lab feedback loop that improves the models over time. Be specific about what your AI does and connect every computational claim to biological confirmation, then match the burden of proof to your round — team and data thesis at seed, a working validated loop at Series A, real programs in or near the clinic at Series B. Vague AI optimism reads as naive to skeptics; named limitations plus a specific reason your approach overcomes them reads as credible to the whole table.

Investors weigh a defensible data moat (datasets a well-funded competitor could not rebuild in twelve months), a validated wet-lab loop (predictions confirmed by physical experiments), capital efficiency (an attractive cost-per-IND trajectory), external validation (pharma pilots or partnerships, a notable scientific co-founder, revenue, or competitive benchmark wins), and a credible regulatory strategy under the FDA’s emerging AI framework. The AI label alone is no longer sufficient — each dimension requires specific, verifiable evidence.

AI washing is attaching AI language to a company without meaningful underlying integration — vague claims like “AI-powered drug discovery” with no specificity about the data, the model, or biological confirmation of outputs. Founders avoid it by leading with the proprietary data asset rather than the model, being technically precise about what the AI does, showing that computational predictions were confirmed in real biology, and naming honestly what the AI cannot do. In a skeptical year, that rigor is the credibility signal.

Pick one as primary. If AI is the core engine producing many programs, you are a platform company, valued on pipeline optionality and data-moat defensibility — but ground the story with at least one concrete asset so it does not sound like vaporware. If you are fundamentally a therapeutics company using AI to move faster, you are an asset company, valued on the risk-adjusted NPV of your lead candidates, with AI as a credible accelerant rather than the headline. You can be a platform with a lead asset or an asset company with a computational edge, but investors punish founders who blur the two because it signals they do not know what they are.

Both are now central. With no AI-discovered drug yet through clinical trials as of early 2026, investor diligence explicitly assesses wet-lab execution — a closed loop where predictions are tested against physical experiments fast enough to retrain the models is among the strongest early signals available. Capital efficiency has become the institutional yardstick for AI-native companies: a cost-per-IND well below traditional benchmarks lowers the risk on every dollar an investor commits, which is exactly what a cautious 2026 market wants to hear.

Sources

  • Clinical-trial failure rate (~85%) and the 10–15-year development timeline; ~60% analyst probability of the first AI-discovered drug winning approval by 2027–28 — PitchBook and buildmvpfast
  • 68% of executives citing poor data quality and governance as the main reason AI initiatives fail — buildmvpfast
  • Cost-per-IND benchmarks (under $50M for AI-native firms vs. upward of $200M for traditional peers) — DrugPatentWatch
  • Precedence Research AI-investment projections ($2.51B in 2026, $16.49B by 2034) — Quartz
  • Drug Target Review’s 2026 “inflection point” characterization — Drug Target Review
  • “Year of deployment” framing for 2026 — GEN

Share

Recent Posts